High tumor burden, Immunotherapy, KEYTRUDA, Pembrolizumab, TMB-H

Pembrolizumab approved for use in any cancer with a high tumor mutational burden

July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any cancer with a high mutational burden (TMB-H). The new authorization is f..

2018 ASCO annual meeting, ASCO meeting, cetuximab, erbitux, focal reduction, HNSCC, Pabosini

Pabosini plus cetuximab for head and neck cancer treatment with 70% focal reduction

According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent  recurrent/metastatic head and ne..

nitrosonornicotinine, Smoking, tobacco-specific nitrosamines

Both e-cigarettes and ordinary tobacco are associated with oral cancer

At the 96th Congress of the International Association for Dental Research (IADR), Benjamin Chaffee of the University of California, San Francisco published a report on nicotine and carcinogens in tobacco.Tobacco use is still the m..

EphB4-ephrin-B2 inhibitor treatment, New technology

New ways to fight recurrent head and neck cancer

Even with surgery,  radiotherapy, chemotherapy, and/or gene-targeted therapy (such as cetuximab), the five-year survival rate for locally advanced head and neck cancer is only 46%. Usually, the treatment is good at first, but the..

Citrus oil may help relieve dry mouth symptoms caused by radiation therapy in head and neck cancer

According to a new study by Stanford University School of Medicine, a compound found in citrus oil may help relieve dry mouth symptoms caused by radiation therapy in head and neck cancer patients. The oil cells of citrus peel are..

Nivolumab combined with ipilimumab was the first successful treatment for head and neck cancer

In patients with metastatic malignant melanoma, the combination of ipilimumab ( CTLA4 antibody) and programmed death (PD)-1 inhibitor nivolumab can significantly improve the prognosis compared with monotherapy . Based on these..

Research progress of rare tumor-head and neck cancer drugs

Compared with other malignant tumors such as non-small cell lung cancer (NSCLC) and breast cancer, head and neck squamous cell carcinoma (HNSCC) is relatively rare in the United States. There are about 500,000 cases worldwide eac..

Can patients with head and neck cancer enjoy spicy hot pot during proton therapy?

Mr. Xu is a typical Chongqing native. He is naturally spicy and unhappy. Among all the spicy foods, Chongqing spicy hot pot is his favorite. However, unfortunately, a malignant tumor with a parotid gland was found, which is a ty..

The expression of PD-L1 in CTC of patients with head and neck squamous cell carcinoma is associated with prognosis

The University of Athens Strati A et al. reported that whether PD-L1 is overexpressed in circulating tumor cells (CTC) can provide more feasible and important prognostic  information for patients with head and neck squamous cell ..

What factors affect head and neck cancer surgery? Do doctors turn to palliative care?

The report by Kershena Liao of Baylor College of Medicine in the United States and more fully understand the process of head and neck oncologists considering switching to  palliative care, which can help to improve this complex p..